WST Q3 deep dive: Biologics and regulatory tailwinds fuel margin expansion, HVP mix shift continues

What happened: West Pharmaceutical Services (NYSE:WST) reported better-than-expected Q3 2026 revenue and raised its full-year revenue and adjusted EPS guidance. Key numbers: Revenue $874.5 million, up 8.7% year on year, versus estimates of $827.1 million. Adjusted EPS $2.66 versus $2.20 expected. Why it matters: Management attributed growth to demand for high-value product components, especially in biologics and GLP-1 therapies, and cited regulatory-driven upgrades as a multi-year tailwind. The operating margin expanded sharply year on year. Market: -1.0% today ($412.62), +49.5% YTD, 1.7x vol — as of 22:46 UTC Verified: Q3_2026 (Oct 29) EPS $2.66 vs $2.20 est, +21.1% beat; next print ~Jan 28

West Pharmaceutical Services (NYSE:WST) reported better-than-expected Q3 2026 revenue and raised its full-year revenue and adjusted EPS guidance.

Management attributed growth to demand for high-value product components, especially in biologics and GLP-1 therapies, and cited regulatory-driven upgrades as a multi-year tailwind. The operating margin expanded sharply year on year. Market: -1.0% today ($412.62), +49.5% YTD, 1.7x vol — as of 22:46 UTC Verified: Q3_2026 (Oct 29) EPS $2.66 vs $2.20 est, +21.1% beat; next print ~Jan 28